Inclusion-body myositis
暂无分享,去创建一个
[1] Dominic M. Walsh,et al. Certain Inhibitors of Synthetic Amyloid β-Peptide (Aβ) Fibrillogenesis Block Oligomerization of Natural Aβ and Thereby Rescue Long-Term Potentiation , 2005, The Journal of Neuroscience.
[2] Z. Simmons,et al. Sporadic inclusion body myositis and hereditary inclusion body myopathy. , 2002, Journal of clinical neuromuscular disease.
[3] G. Glenner,et al. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .
[4] Richard J. Barohn,et al. Inclusion body myositis , 2000, Current treatment options in neurology.
[5] J. Growdon,et al. Elevation of cystatin C in susceptible neurons in Alzheimer's disease. , 2001, The American journal of pathology.
[6] C. Link,et al. Interaction of intracellular β amyloid peptide with chaperone proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] G. Glenner,et al. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.
[8] T. Braun,et al. Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.
[9] R. Kopito,et al. Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.
[10] Andrew G. Engel,et al. αB-Crystallin immunolocalization yields new insights into inclusion body myositis , 2000, Neurology.
[11] C. Glabe. Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. , 2005, Sub-cellular biochemistry.
[12] R. Griggs. The current status of treatment for inclusion-body myositis , 2006, Neurology.
[13] R. Kaufman,et al. ER stress and the unfolded protein response. , 2005, Mutation research.
[14] L. K. Baker,et al. Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.
[15] B. Ghetti,et al. Codeposition of Cystatin C with Amyloid‐β Protein in the Brain of Alzheimer Disease Patients , 2001, Journal of neuropathology and experimental neurology.
[16] Changcheng Song,et al. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. , 2004, Journal of structural biology.
[17] K. Hall,et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer’s disease: A population-based study of African Americans , 2000, Neurology.
[18] W. Markesbery,et al. Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.
[19] W. Engel,et al. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-&bgr;, misfolded proteins, predisposing genes, and aging , 2003, Current opinion in rheumatology.
[20] W. Klein. ADDLs & protofibrils—the missing links? , 2002, Neurobiology of Aging.
[21] L. Pasquini,et al. Relationship between β-amyloid degradation and the 26S proteasome in neural cells , 2003, Experimental Neurology.
[22] W. Engel,et al. βAPP gene transfer into cultured human muscle induces inclusion‐body myositis aspects , 1997 .
[23] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[24] Jason E Gestwicki,et al. Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid ß Aggregation , 2004, Science.
[25] A. Goldberg,et al. Cellular Defenses against Unfolded Proteins A Cell Biologist Thinks about Neurodegenerative Diseases , 2001, Neuron.
[26] Julio C. Echegoyen,et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of βAPP in skeletal muscle , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Cuello,et al. Intracellular A-beta amyloid, A sign for worse things to come? , 2002, Molecular Neurobiology.
[28] C. Pickart,et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] W. Engel,et al. Inclusion‐Body Myositis: Newest Concepts of Pathogenesis and Relation to Aging and Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.
[30] R. Barbour,et al. Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.
[31] P. Højrup,et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. , 2004, The Journal of biological chemistry.
[32] D. Ron,et al. Conformational disease , 2000, Nature Cell Biology.
[33] P. Greengard,et al. Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .
[34] J R Lindsey,et al. Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. , 1998, The American journal of pathology.
[35] Aaron Ciechanover,et al. The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.
[36] E. Hol,et al. Disease‐specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[37] Rahul S. Rajan,et al. Specificity in intracellular protein aggregation and inclusion body formation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] Kucharz Ej. [Inclusion body myositis]. , 1998, Polskie Archiwum Medycyny Wewnetrznej.
[39] E. Hol,et al. Molecular misreading: a new type of transcript mutation expressed during aging , 2000, Neurobiology of Aging.
[40] R. Nitsch,et al. Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's disease , 2003, Journal of neurochemistry.
[41] M. Dalakas. The molecular and cellular pathology of inflammatory muscle diseases. , 2001, Current opinion in pharmacology.
[42] P M Steinert,et al. Sporadic Inclusion Body Myositis Correlates with Increased Expression and Cross-linking by Transglutaminases 1 and 2* , 2000, The Journal of Biological Chemistry.
[43] W. Engel,et al. Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle , 2002, Neurology.
[44] S. Silberstein,et al. Acute migraine treatment with droperidol , 2003, Neurology.
[45] J. Buxbaum,et al. BACE1 and BACE2 in pathologic and normal human muscle , 2003, Experimental Neurology.
[46] A. Fink. Chaperone-mediated protein folding. , 1999, Physiological reviews.
[47] C. Fielding,et al. Cholesterol and caveolae: structural and functional relationships. , 2000, Biochimica et biophysica acta.
[48] W. Engel,et al. Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice. , 1998, The American journal of pathology.
[49] W. Baumeister,et al. The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.
[50] V. Askanas,et al. Cystatin C colocalizes with amyloid‐β and coimmunoprecipitates with amyloid‐β precursor protein in sporadic inclusion‐body myositis muscles , 2003 .
[51] W. Engel,et al. Does Overexpression of βAPP in Aging Muscle Have a Pathogenic Role and a Relevance to Alzheimer’s Disease? : Clues from Inclusion Body Myositis, Cultured Human Muscle, and Transgenic Mice , 1998 .
[52] E. Sztul,et al. Hassles with Taking Out the Garbage: Aggravating Aggresomes , 2002, Traffic.
[53] W. Engel,et al. Myostatin is increased and complexes with amyloid-β within sporadic inclusion-body myositis muscle fibers , 2005, Acta Neuropathologica.
[54] W. Engel,et al. Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion‐body myopathies , 1998, Neuroreport.
[55] W. Engel,et al. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. , 2004, The American journal of pathology.
[56] J. Buxbaum,et al. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis , 2001, The Lancet.
[57] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[58] R. Kopito,et al. Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.
[59] George M. Martin,et al. Transgenic Mice Over-Expressing the C-99 Fragment of βPP with an α-Secretase Site Mutation Develop a Myopathy Similar to Human Inclusion Body Myositis , 1998 .
[60] A. Pockley,et al. Heat shock proteins in health and disease: therapeutic targets or therapeutic agents? , 2001, Expert Reviews in Molecular Medicine.
[61] F. Grosveld,et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. , 1998, Science.
[62] Sangram S. Sisodia,et al. γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in? , 2002, Nature Reviews Neuroscience.
[63] A. Pestronk,et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.
[64] P. Greengard,et al. Intraneuronal Abeta42 accumulation in human brain. , 2000, The American journal of pathology.
[65] W. Engel,et al. Novel Immunolocalization of α‐Synuclein in Human Muscle of Inclusion‐Body Myositis, Regenerating and Necrotic Muscle Fibers, and at Neuromuscular Junctions , 2000, Journal of neuropathology and experimental neurology.
[66] C. Southan,et al. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. , 2000, Molecular and cellular neurosciences.
[67] E. Holme,et al. Mitochondrial DNA Deletions in Muscle Fibers in Inclusion Body Myositis , 1995, Journal of neuropathology and experimental neurology.
[68] S. Lipton,et al. Molecular pathways to neurodegeneration , 2004, Nature Medicine.
[69] E. Masliah,et al. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases , 2007, NeuroMolecular Medicine.
[70] W. Engel,et al. Inclusion-body myositis , 2006, Neurology.
[71] W. Engel,et al. beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. , 1993, Neuroreport.
[72] F. Mastaglia,et al. Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects , 2003, Muscle & nerve.
[73] W. Engel,et al. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[74] P. Crofton,et al. Diagnostic Utility of a Low-Dose Gonadotropin-Releasing Hormone Test in the Context of Puberty Disorders , 2004, Hormone Research in Paediatrics.
[75] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[76] G. Vattemi,et al. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers , 2004, Neurology.
[77] W. Engel,et al. Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms , 2002, Current opinion in neurology.
[78] H. Atkins,et al. Suppressing immunity in advancing MS , 2004, Neurology.
[79] W. Engel,et al. Strong immunoreactivity of β-amyloid precursor protein, including the β-amyloid protein sequence, at human neuromuscular junctions , 1992, Neuroscience Letters.
[80] D. Selkoe. Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman , 2003, Neurochemical Research.
[81] J. Tang,et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[82] R. Ellis,et al. Medicine: Danger — misfolding proteins , 2002, Nature.
[83] M. Franceschi,et al. Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms , 2002, Neurobiology of Aging.
[84] S. Bhasin,et al. Role of myostatin in metabolism , 2004, Current opinion in clinical nutrition and metabolic care.
[85] P. Højrup,et al. Proteasomal Inhibition by α-Synuclein Filaments and Oligomers* , 2004, Journal of Biological Chemistry.
[86] W. W. Jong,et al. The Molecular Chaperone aB-crystallin Enhances Amyloid Neurotoxicity , 1999 .
[87] A. Cuello. Intracellular and Extracellular Aβ, a Tale of Two Neuropathologies , 2005, Brain pathology.
[88] Pietro Fratta,et al. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. , 2005, The American journal of pathology.
[89] G. Martin,et al. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. , 1998, The American journal of pathology.
[90] S. Dimauro,et al. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: A study of 56 patients , 1996, Annals of neurology.